21 CFR 520.2475
§ 520.2475 Toceranib.
United States · 21 CFR — Food and Drugs · Status: effective
Cite this
- Citation
- 21 CFR 520.2475, § 520.2475 Toceranib, United States, version 1 as recorded 2026-07-09, yourstate.us, https://yourstate.us/provision/87359
- Permanent ID
ys:prov:87359@1- SHA-256
7e9f3e1237bfcb26fc60b059ea1b47dc2c7a78a1fef428b8d78eb0cebb335c06
The hash is SHA-256 of this version's text, with every run of whitespace collapsed to a single space and the ends trimmed. The ID always leads back here, and checking it says whether the text you cited is still the current version.
Full text
(a) Specifications. Each tablet contains 10, 15, or 50 milligrams (mg) toceranib as toceranib phosphate.
(b) Sponsor. See No. 054771 in § 510.600 of this chapter.
(c) Conditions of use—(1) Dogs—(i) Amount. Administer an initial dose of 3.25 mg per kilogram (1.48 mg per pound) body weight, orally every other day.
(ii) Indications for use. For the treatment of Patnaik grade II or III, recurrent, cutaneous mast cell tumors with or without regional lymph node involvement.
(iii) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
(2) [Reserved]
Legislative history
This is a federal regulation, adopted through agency rulemaking under the Administrative Procedure Act — not enacted by a recorded vote of Congress.